Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor

Publisher： Karger

E-ISSN： 1421-9670|42|5|379-388

ISSN： 0250-8095

Source： American Journal of Nephrology, Vol.42, Iss.5, 2015-0, pp. : 379-388

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Analysis of α-Klotho, Fibroblast Growth Factor-, Vitamin-D and Calcium-Sensing Receptor in 70 Patients with Secondary Hyperparathyroidism

By  

Kidney and Blood Pressure Research, Vol. 37, Iss. 1, 2013-03 ,pp. : 84-94

Karger

Access to resources Recommend Favorite

Effectiveness of Intravenous and Subcutaneous Calcitriol inthe Treatment of Secondary Hyperparathyroidism

By  

Nephron, Vol. 80, Iss. 1, 1998-09 ,pp. : 119-120

Karger

Access to resources Recommend Favorite

Clinical Effect of Intravenous Calcitriol Administration on Secondary Hyperparathyroidism

By  

Nephron, Vol. 90, Iss. 4, 2002-04 ,pp. : 413-423

Karger

Access to resources Recommend Favorite

Paricalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients on Sevelamer Hydrochloride: Which Dialysate Calcium Concentration to Use?

By  

Blood Purification, Vol. 27, Iss. 2, 2009-01 ,pp. : 182-186

Karger

Access to resources Recommend Favorite

Treatment of Secondary Hyperparathyroidism in Hemodialyzed Patients with High-Dose Calcium Carbonate without Vitamin D3 Supplements

By  

American Journal of Nephrology, Vol. 19, Iss. 3, 1999-06 ,pp. : 428-432

Karger

Access to resources Recommend Favorite